GSK says split plans on track, forecasts dip in profit this year
The company, which earlier in the day announced a tie-up with CureVac to develop a Covid-19 vaccine, reported a 2% fall in turnover in the three months ended Dec. 31. Adjusted earnings came in at 23.3 pence per share
Photo: Collected
Britain's GSK said on Wednesday its plan to split into two businesses was on track, as the drugmaker aiding in Covid-19 vaccine developments forecast 2021 profit to fall by a mid- to high-single digit percentage.
The company, which earlier in the day announced a tie-up with CureVac to develop a Covid-19 vaccine, reported a 2% fall in turnover in the three months ended Dec. 31. Adjusted earnings came in at 23.3 pence per share.
Keep updated, follow The Business Standard's Google news channel
